Particle Size News and Research

RSS

Nanosize titanates may inhibit growth of oral cancer and bacterial cell lines

Sometimes bigger isn't better. Researchers at the U.S. Department of Energy's Savannah River National Laboratory have successfully shown that they can replace useful little particles of monosodium titanate (MST) with even tinier nano-sized particles, making them even more useful for a variety of applications.

1 Feb 2012

Health influence of combustion conditions in wood-burning stoves

Wood-burning stoves are a popular source of heating in many countries. However in recent years there has been much debate about the potential negative health effects associated with wood smoke. A Norwegian researcher has studied the influence of combustion conditions on the emissions and their health effects.

18 Jan 2012

Latest advances in cardiovascular medicine, science and education to be presented at AHA 2011

Perelman School of Medicine at the University of Pennsylvania faculty will be involved in presenting research findings on the latest advances in cardiovascular medicine, science, and education at the 2011 American Heart Association Scientific Sessions, in Orlando, FL, November 12 - 16, 2011.

14 Nov 2011

Results of Phase 2 program to develop NSAIDs to be reported at ACR annual meeting

The results of the Phase 2 program sponsored by Iroko Pharmaceuticals to develop novel, lower-dose formulations of a widely used class of pain medicines will be reported November 7th at the annual meeting of the American College of Rheumatology in Chicago.

5 Nov 2011

Azantis introduces reduced glutathione and vitamin C liposomal products

Azantis launched today two innovative liposomal products: reduced glutathione and vitamin C. Both oral supplements are formulated in liposomal form to maximize absorption and to minimize side effects. Azantis, a leading phospholipid manufacturer, markets the liposomal products to resellers targeting the health care practitioner channel.

1 Nov 2011

Encap Drug Delivery and Lena Nanoceutics to develop new drug delivery technology

Encap Drug Delivery and Lena Nanoceutics today announce a collaboration agreement to develop a new drug delivery technology (Nano-Capsules) which combines Lena’s proprietary nano-particle engineering technology with Encap’s liquid filled hard capsule technology.

24 Oct 2011

Laser-based analysis method can detect optical pressure differences in blood cells

U.S. Naval Research Laboratory researchers Dr. Sean J. Hart, Dr. Colin G. Hebert and Mr. Alex Terray have developed a laser-based analysis method that can detect optical pressure differences between populations or classes of blood cells that does not rely on prior knowledge, antibodies, or fluorescent labels for discrimination.

13 Oct 2011

Diclofenac in nano-formulated doses provides effective pain relief

A novel formulation of diclofenac provides pain relief at lower-than-standard doses during a Phase II clinical study as reported today at the 2011 World Congress on Osteoarthritis.

16 Sep 2011

Pittsburgh researchers combine Viscotek GPC and Zetasizer Nano in work on novel polymers for drug delivery

Molecular weight and molecular weight distribution measurements are a basic necessity in studying the synthesis of the novel polymers being carried out by researchers at the Department of Bioengineering at the University of Pittsburgh. For the Pittsburgh team, the applications and technical expertise provided by Malvern Panalytical is a significant factor in their use of the company’s Viscotek gel permeation chromatography (GPC) system to characterize polymer molecular weight, prior to applying the Zetasizer Nano for zeta potential measurements to study inter-molecular interactions.

From Malvern Panalytical 18 Aug 2011

Alnylam second quarter revenue decreases to $20.6 million

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter 2011, and company highlights.

From Precision NanoSystems Inc. 2 Aug 2011

'Core-shell' nanoparticles for effective intracellular delivery of RNAi therapeutics

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, together with collaborators at the Massachusetts Institute of Technology (MIT), announced today the publication of new paper describing discovery of "core-shell" nanoparticles for systemic delivery of RNAi therapeutics.

26 Jul 2011

Malvern and Paraytec enter into development and technology licensing agreement

Malvern Panalytical (Malvern Panalytical, UK) and Paraytec Ltd (York, UK) have entered into a development and licensing agreement that will see Paraytec’s ActiPix® technology being added to Malvern Panalytical’s materials characterization portfolio. The agreement will give Malvern Panalytical exclusive rights to further develop, market and sell ActiPix® UV area imaging technology in specific fields of use related to the characterization of complex fluids for applications in biopharmaceuticals, foods and personal care industrial sectors.

From Malvern Panalytical 20 Jul 2011

Pulmatrix introduces novel iSPERSE inhaled dry powder drug delivery platform

Pulmatrix, a clinical stage biotechnology company discovering and developing a new class of therapies for the prevention, treatment and control of respiratory diseases, today announced the launch of iSPERSE, the company's novel inhaled dry powder drug delivery platform.

20 Jun 2011

Nano-formulated indomethacin at lower dose effective in treating pain

A novel, lower-dose formulation of indomethacin, a widely used pain reliever, is absorbed faster by the body than a standard formulation and maintains comparable maximum concentrations in the blood despite being administered at a lower dose, according to a study to be reported here tomorrow at the annual meeting of the American Headache Society.

4 Jun 2011

Iroko Pharmaceuticals announces acquisition of iCeutica

Iroko Pharmaceuticals, LLC today announces that it has acquired iCeutica, Inc. to further strengthen Iroko's position as the leading developer of novel, low-dose non-steroidal anti-inflammatory drugs.

29 Apr 2011

Pharmatek purchases spray dryer for drug formulation and manufacturing

Pharmatek Laboratories, Inc., a premier contract development and manufacturing organization supporting the pharmaceutical industry, announced that it has added spray drying to its drug formulation and manufacturing capabilities. The company has purchased a Buchi B-290 Mini Spray Dryer for formulation feasibility studies and small-scale clinical manufacture. This technology can be used for both oral and parenteral dosage forms.

25 Apr 2011

Alnylam, Precision NanoSystems enter collaboration for discovery of novel small lipid nanoparticles

Precision NanoSystems, Inc. and Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the two companies have formed an exclusive collaboration focused on the discovery and development of novel lipid nanoparticles, known as small lipid nanoparticles ("sLNPs"), using microfluidics technology.

From Precision NanoSystems Inc. 20 Apr 2011

Morphologi G3 Raman chemical identification of contaminant particles

A new application note describing ‘Raman chemical identification of contaminant particles’ is now available on the Malvern Panalytical website. It highlights the ability of the company’s Morphologi G3 equipped with Raman microprobe accessory to target particulate impurities, an area of considerable interest to manufacturers of complex, high value products where control of particle size and shape is crucial.

From Malvern Panalytical 25 Mar 2011

Covaris launches Bench-top SF220 Formulation Processing System

Covaris Incorporated today announced the introduction of the Bench-top SF220 High Performance Formulation Processing System.

25 Mar 2011

Gates Foundation makes $10M PRI in Liquidia to support development of vaccines, therapeutics

Liquidia Technologies today announced the Bill & Melinda Gates Foundation has made a $10 million program-related investment in the company to support the development and commercialization of safer and more effective vaccines and therapeutics. This follows recent announcements of the first Liquidia clinical trial of its lead seasonal flu candidate (LIQ001) and a collaborative agreement with the PATH Malaria Vaccine Initiative.

5 Mar 2011